Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
NCT ID: NCT03568331
Last Updated: 2024-05-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
375 participants
INTERVENTIONAL
2018-07-09
2019-12-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
NCT04140695
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
NCT02004041
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
NCT05121480
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
NCT06723405
A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis
NCT02094235
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tradipitant
Tradipitant
Oral Capsule
Placebo
Placebo
Oral Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tradipitant
Oral Capsule
Placebo
Oral Capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with atopic dermatitis;
* Suffering from chronic pruritus;
* Body Mass Index (BMI) of ≥18 and ≤40 kg/m2
Exclusion Criteria
* A positive test for drugs of abuse at the screening or evaluation visits;
* Exposure to any investigational medication in the past 8 weeks
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Birmingham, Alabama, United States
Vanda Investigational Site
Birmingham, Alabama, United States
Vanda Investigational Site
Tempe, Arizona, United States
Vanda Investigational Site
Encino, California, United States
Vanda Investigational Site
Fountain Valley, California, United States
Vanda Investigational Site
Fremont, California, United States
Vanda Investigational Site
Laguna Hills, California, United States
Vanda Investigational Site
Lomita, California, United States
Vanda Investigational Site
Long Beach, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
Los Angeles, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
Santa Monica, California, United States
Vanda Investigational Site
Denver, Colorado, United States
Vanda Investigational Site
Aventura, Florida, United States
Vanda Investigational Site
Clearwater, Florida, United States
Vanda Investigational Site
Fort Lauderdale, Florida, United States
Vanda Investigational Site
Hialeah, Florida, United States
Vanda Investigational Site
Miami, Florida, United States
Vanda Investigational Site
Miami, Florida, United States
Vanda Investigational Site
Miramar, Florida, United States
Vanda Investigational Site
Ormond Beach, Florida, United States
Vanda Investigational Site
South Miami, Florida, United States
Vanda Investigational Site
Tampa, Florida, United States
Vanda Investigational Site
Savannah, Georgia, United States
Vanda Investigational Site
Boise, Idaho, United States
Vanda Investigational Site
Normal, Illinois, United States
Vanda Investigational Site
Skokie, Illinois, United States
Vanda Investigational Site
Plainfield, Indiana, United States
Vanda Investigational Site
Crowley, Louisiana, United States
Vanda Investigational Site
Rockville, Maryland, United States
Vanda Investigational Site
Towson, Maryland, United States
Vanda Investigational Site
Beverly, Massachusetts, United States
Vanda Investigational Site
Brighton, Massachusetts, United States
Vanda Investigational Site
Fort Gratiot, Michigan, United States
Vanda Investigational Site
Saint Joseph, Missouri, United States
Vanda Investigational Site
St Louis, Missouri, United States
Vanda Investigational Site
Omaha, Nebraska, United States
Vanda Investigational Site
Las Vegas, Nevada, United States
Vanda Investigational Site
Las Vegas, Nevada, United States
Vanda Investigational Site
Berlin, New Jersey, United States
Vanda Investigational Site
Verona, New Jersey, United States
Vanda Investigational Site
Brooklyn, New York, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
Charlotte, North Carolina, United States
Vanda Investigational Site
High Point, North Carolina, United States
Vanda Investigational Site
Wilmington, North Carolina, United States
Vanda Investigational Site
Cincinnati, Ohio, United States
Vanda Investigational Site
Dayton, Ohio, United States
Vanda Investigational Site
Oklahoma City, Oklahoma, United States
Vanda Investigational Site
Tulsa, Oklahoma, United States
Vanda Investigational Site
Philadelphia, Pennsylvania, United States
Vanda Investigational Site
Pittsburgh, Pennsylvania, United States
Vanda Investigational Site
Johnston, Rhode Island, United States
Vanda Investigational Site
North Charleston, South Carolina, United States
Vanda Investigational Site
Spartanburg, South Carolina, United States
Vanda Investigational Site
Chattanooga, Tennessee, United States
Vanda Investigational Site
Nashville, Tennessee, United States
Vanda Investigational Site
Dallas, Texas, United States
Vanda Investigational Site
Pflugerville, Texas, United States
Vanda Investigational Site
San Antonio, Texas, United States
Vanda Investigational Site
San Antonio, Texas, United States
Vanda Investigational Site
West Jordan, Utah, United States
Vanda Investigational Site
South Burlington, Vermont, United States
Vanda Investigational Site
Newport News, Virginia, United States
Vanda Investigational Site
Norfolk, Virginia, United States
Vanda Investigational Site
Richmond, Virginia, United States
Vanda Investigational Site
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Study Webpage
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EPIONE
Identifier Type: OTHER
Identifier Source: secondary_id
VP-VLY-686-3101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.